Subscribe

FluoGuide A/S (FLUO.ST)

SEK35.20 +1.40 (+4.14%)
DK STO Healthcare Medical - Instruments & Supplies
Address Ole MaalOees Vej 3 2200
Copenhagen, DK
CEO Morten Albrechtsen
Website fluoguide.com
IPO 2019-06-17
ISIN DK0061123312

Explore sections of this company profile

Description

FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grade glioma (a type of brain cancer) and has also advanced to Phase II development for lung cancer. The company is further developing FG002, a preclinical-stage product that utilizes novel uPAR-targeted luminescent technology to enable surgeons to distinguish cancerous from healthy tissue during operations. FluoGuide A/S has established key collaborations, including an agreement with Linköping University Hospital to support the Phase I/II clinical evaluation of FG001 for the surgical removal of brain tumors, and an ongoing partnership with Copenhagen University Hospital. The company was founded in 2018 and maintains its headquarters in Copenhagen, Denmark.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
SEK35.20 +1.40 (+4.14%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7.3K
Beta
0.90
Float Shares
9.98M
Free Float %
72.6%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+2.76% -1.21% -5.54% +14.25% +10.54% +10.84% -2.39% -53.63% -57.84% +752.08% +752.08%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
35.20
DCF (Unlevered) 2.42 -93.1%
DCF (Levered) 2.12 -94.0%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2026-05 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
6.81
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Instruments & Supplies: +7.9%
    -100.0%
  • ✗
    EPS growth Medical - Instruments & Supplies: +16.3%
    -28.7% Q1'26: -10.8% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%
    —
  • ✗
    EBIT margin Medical - Instruments & Supplies: +13.5%
    —
  • ✗
    ROIC Medical - Instruments & Supplies: +6.0%
    -1,020.6% Q1'26: -550.2% (vs Q1'25)
  • ✗
    Share dilution Medical - Instruments & Supplies: +0.1%
    +8.4% Q1'26: +20.2% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×
    -0.70× Q1'26: -0.55× (vs Q1'25)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.89) × ERP
WACC = 93% × Ke + 7% × Kd (15.9%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 2.42 Current price: 35.20
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana.
Revenue
385.0K
est: 385.0K (+0.0%)
—
151.8K
151.8K – 151.8K
22.50M
22.50M – 22.50M
+14,718.2% YoY
EBITDA
-32.81M
est: -231.0K (-14,104.3%)
-40.42M
-91.1K
-91.1K – -91.1K
-13.50M
-13.50M – -13.50M
-14,718.2% YoY
EBIT
-33.04M
est: -231.0K (-14,202.6%)
-40.99M
-91.1K
-91.1K – -91.1K
-13.50M
-13.50M – -13.50M
-14,718.2% YoY
Net Income
-28.96M
est: -21.93M (-32.1%)
-40.39M
est: -23.28M (-73.5%)
-29.10M
-29.10M – -29.10M
-25.0% YoY
24.25M
24.25M – 24.25M
+183.3% YoY
SGA
32.97M
est: 15.14M (+117.7%)
21.47M
5.97M
5.97M – 5.97M
885.11M
885.11M – 885.11M
+14,718.2% YoY
EPS
-2.23
est: -1.69 (-31.9%)
-2.87
est: -1.66 (-73.3%)
-2.07
-2.07 – -2.07
-25.0% YoY
1.73
1.73 – 1.73
+183.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-28 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-27 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5
2026-05-26 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5
2026-05-25 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5
2026-05-22 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5
2026-05-21 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5
2026-05-20 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5
2026-05-19 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5
2026-05-18 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5
2026-05-15 C- 1/5 3/5 1/5 1/5 2/5 1/5 1/5
2026-05-13 C- 1/5 2/5 1/5 1/5 2/5 1/5 1/5
2026-05-12 C- 1/5 2/5 1/5 1/5 2/5 1/5 1/5
2026-05-11 C- 1/5 2/5 1/5 1/5 2/5 1/5 1/5
2026-05-08 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 D+ 1/5 2/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-37.44M
OE per share TTM
-2.56
Owner's Yield
-5.59%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
21.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
Shares Outstanding
13.75M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Andreas Kjaer CSO, Head of Scientific Advisory Board & Director — —
Donna Haire Chief Operating Officer — female
Grethe Nørskov Rasmussen Chief Development Officer — —
Morten Albrechtsen Chief Executive Officer — male
Ole Larsen Cand. merc. Chief Financial Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Instruments & Supplies